LL-37 5mg

Research

Scientific Research on LL-37 (the only cathelicidin family peptide found in humans, widely studied for its pleiotropic properties)

LL-37 is a 37-amino acid antimicrobial peptide (AMP), derived from the proteolytic cleavage of the precursor protein hCAP-18 (human Cationic Antimicrobial Protein, 18 kDa). It features an amphipathic alpha-helical structure and a net positive charge (+6). It is expressed predominantly in neutrophils, epithelial cells, and immune cells in response to infection and inflammation, acting as a critical component of innate immunity.

Mechanism of Action and Inhibition

LL-37 operates through two distinct mechanisms:

• Direct Antimicrobial Action: Due to its amphipathic nature, LL-37 interacts with bacterial membranes (rich in anionic lipids). It inserts into the lipid bilayer following either the "carpet model" or "toroidal pore formation," leading to osmotic lysis of the pathogen.
• Immune Modulation: It acts as a ligand for various cellular receptors, including FPR2 (Formyl Peptide Receptor 2) and the P2X7 purinergic receptor. This results in immune cell chemotaxis and modulation of cytokine release.
• Inhibition: LL-37 activity can be inhibited by bacterial proteases and by high levels of salts or glycosaminoglycans in the extracellular matrix, which can sequester the peptide and prevent its interaction with target membranes.

Metabolic Impacts Scientifically Investigated to Date

Investigations into LL-37 reveal profound impacts on tissue and inflammatory metabolism:

1. Angiogenesis: LL-37 stimulates the formation of new blood vessels by interacting with receptors on endothelial cells, a vital process for tissue oxygenation.
2. Wound Healing and Re-epithelialization: It promotes keratinocyte proliferation and migration, accelerating wound closure.
3. Endotoxin Neutralization: It possesses high affinity for Lipopolysaccharide (LPS) from Gram-negative bacteria, preventing LPS from activating the TLR4 receptor and triggering a cytokine storm (sepsis).

Investigations in Oncological Models

The role of LL-37 in oncology is complex and tumor microenvironment-dependent, exhibiting a dual nature:

• Pro-tumorigenic Effect: In lung, breast, and ovarian cancers, elevated LL-37 levels can promote cell proliferation and tumor angiogenesis, aiding neoplastic progression.
• Anti-tumorigenic Effect: In contrast, models of colon and gastric cancer suggest that LL-37 can induce apoptosis in malignant cells and suppress tumor growth through the activation of specific pro-apoptotic signaling pathways.

Specific Action of the LL-37 Peptide

The most notable specific action is its ability to bind and neutralize exogenous nucleic acids. LL-37 can form complexes with circulating DNA or RNA (often released during cell death or viral infection), facilitating their entry into dendritic cells via TLR9 and TLR7 receptors. This action is a major focus of research in autoimmune diseases such as psoriasis.

Pharmacokinetic Considerations in Research

• Stability: In biological fluids, LL-37 is susceptible to degradation by proteases such as neutrophil elastase and cathepsins, which limits its systemic half-life.
• Bioavailability: Due to its size and charge, systemic administration faces stability challenges; therefore, topical application or the use of delivery vehicles (nanoparticles and liposomes) are the most explored routes in research.
• Elimination: Fragments resulting from proteolytic cleavage are processed and eliminated via conventional renal pathways.

Other Important Research Relationships

LL-37 has an important synergistic relationship with Vitamin D. The expression of the CAMP gene (which encodes hCAP-18) is directly regulated by the vitamin D receptor (VDR). Research indicates that Vitamin D deficiency compromises LL-37 production, reducing the innate capacity to combat respiratory pathogens.

Final Considerations

LL-37 transcends the simple definition of a "natural antibiotic," positioning itself as a central signaling molecule at the interface between innate and adaptive immunity. Although its dual nature in oncology requires caution, its potential as a wound-healing agent and bacterial toxin neutralizer makes it one of the most versatile peptides in current biomedical research.

References

• Vandamme, D., Landuyt, B., & Luyten, W. (2012). A critical review on the role of LL-37 in immunity and oncology. Peptides, 37. https://doi.org/10.1016/j.peptides.2012.08.013
• Koczulla, R., von Degenfeld, G., & Kupatt, C. (2003). Angiogenesis induced by the human cathelicidin LL-37. Journal of Clinical Investigation, 111. https://doi.org/10.1172/JCI16609
• Zhang, Z., Cherryholmes, G., & Shively, J. E. (2024). Signaling mechanisms and impact of LL-37 on the tumor microenvironment. International Journal of Molecular Sciences, 25. https://doi.org/10.3390/ijms25042100